HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver Q1

This article was originally published in The Rose Sheet

Executive Summary

Firm has "absolutely no intent whatsoever to consider a sale" of the consumer products business in light of the company's planned spin-off of Sally Beauty, Alberto President and CEO Howard Bernick states during first quarter sales and earnings call Jan. 26. Company recently announced it will complete sale of Sally to Regis Corporation this spring, simultaneous to Bernick's retirement (1"The Rose Sheet" Jan. 16, 2006, p. 3). In Q1, consumer product sales grew 5% to $318.9 mil., while earnings before income taxes advanced 14.7% to $31.4 mil., according to the firm. Growth of the unit was driven in part by Tresemme, which had "very strong" double-digit increases in the U.S. and Europe, firm notes. Net sales during the period were up 6% to $898.3 mil., while net earnings grew 5.4% to $52.1 mil. Firm plans to spend more than $310 mil. on advertising this year, Bernick notes...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel